Off-label use of drugs in regional anesthesia: A need for setting up policies.

J Anaesthesiol Clin Pharmacol

Department of Anaesthesiology, BPS GMC, Khanpur Kalan, Sonepat, Haryana, India.

Published: January 2017

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791255PMC
http://dx.doi.org/10.4103/joacp.JOACP_341_15DOI Listing

Publication Analysis

Top Keywords

off-label drugs
4
drugs regional
4
regional anesthesia
4
anesthesia setting
4
setting policies
4
off-label
1
regional
1
anesthesia
1
setting
1
policies
1

Similar Publications

Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.

Lancet Reg Health Southeast Asia

February 2025

Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

The 2024 Nipah outbreak in Kerala, India-its fifth in six years-and the recurring annual outbreaks in Bangladesh underscore the persistent threat posed by the Nipah virus (NiV) in the region. With a high mortality rate, human-to-human transmission potential, and the widespread presence of bats, the natural reservoir, NiV remains a significant epidemic threat. Despite being a WHO priority pathogen, there has been no systematic effort to improve patient care for NiVD, leading to consistently poor outcomes.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, joint pain, and progressive cartilage and bone erosion. Despite advancements in RA management with disease-modifying antirheumatic drugs (DMARDs) and biologics, some patients remain refractory to conventional treatments. Tetracyclines, such as minocycline and doxycycline, exhibit anti-inflammatory and immunomodulatory properties, making them potential supplementary treatments.

View Article and Find Full Text PDF

Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, specific electroencephalogram (EEG) patterns, and significant cognitive and behavioral impairments. To date, eight anti-seizure medications (ASMs) have been specifically approved by the U.S.

View Article and Find Full Text PDF

Biodegradable polymeric microsphere formulations of full-length anti-VEGF antibody bevacizumab for sustained intraocular delivery.

Drug Deliv Transl Res

January 2025

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA.

Age-related macular degeneration (AMD) is one of the leading causes of central vision loss in the elderly population. Bevacizumab, a full-length humanized monoclonal anti-VEGF antibody, is commonly used off-label drug to treat AMD. However, the dosing regimen of bevacizumab and other anti-VEGF antibodies requires monthly intravitreal injections followed by regular intravitreal injections at 4-16-week intervals.

View Article and Find Full Text PDF

Objective: There is a lack of studies investigating the safety of combination regimens specifically for cardiovascular and cerebrovascular diseases. This study aimed to evaluate the safety of combination drugs for cardiovascular and cerebrovascular diseases using real-world data.

Methods: We analyzed adverse drug reaction data received by the Hubei Adverse Drug Reaction Center from the first quarter of 2014 to the fourth quarter of 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!